Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 71, Issue 20, Pages 3885-3901Publisher
SPRINGER BASEL AG
DOI: 10.1007/s00018-014-1656-6
Keywords
Histone deacetylases (HDACs); Histone deacetylase inhibitor (HDACi); Cell death; Apoptosis; Autophagy
Categories
Funding
- Welch Foundation
- Ellison Medical foundation
- American Cancer Society [RSG-11-274-01-CCG]
- NIH R01 [CA133228]
Ask authors/readers for more resources
Histone deacetylases (HDACs) are a vast family of enzymes involved in chromatin remodeling and have crucial roles in numerous biological processes, largely through their repressive influence on transcription. In addition to modifying histones, HDACs also target many other non-histone protein substrates to regulate gene expression. Recently, HDACs have gained growing attention as HDAC-inhibiting compounds are being developed as promising cancer therapeutics. Histone deacetylase inhibitors (HDACi) have been shown to induce differentiation, cell cycle arrest, apoptosis, autophagy and necrosis in a variety of transformed cell lines. In this review, we mainly discuss how HDACi may elicit a therapeutic response to human cancers through different cell death pathways, in particular, apoptosis and autophagy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available